Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection
Subcutaneous daratumumab may be an effective treatment for cABMR; larger randomized trials are warranted to study its role in the treatment for cABMR in KTRs. dd-cfDNA may be a useful monitoring tool to predict and detect relapses.
Authors
- Alwin Hwai Liang Loh (ORCID: https://orcid.org/0000-0003-3852-040X)
- Wai-Choong Lye
Institutions
- National Kidney Foundation Singapore (SG)
- Singapore General Hospital (SG)
- National Centre for Infectious Diseases (SG)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.ekir.2025.07.009
- Citations
- 6
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.91